1. 1245PDIntratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study. (23rd October 2018) Authors: Diab, A; Haymaker, C; Bernatchez, C; Andtbacka, R H I; Shaheen, M; Johnson, D; Markowitz, J; Puzanov, I; Murthy, R; Johnson, D H; James, M; Chunduru, S; Geib, J; Swann, S; Rahimian, S; Hwu, P Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1306TiPILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. (23rd October 2018) Authors: Ascierto, P A; Arenberger, P; Atkinson, V G; Hansson, J; Kapiteijn, E; Loquai, C; Negrier, S; Shaw, H M; Tarhini, A; Walker, J; Geib, J; Rahimian, S; Swann, S; Diab, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS. (31st January 2022) Authors: Telen, M; Saraf, S; Cruz, K; Idowu, M; Kalfa, T; Osunkwo, I; Hagar, R; Geib, J; Forsyth, S; Schroeder, P; Wu, E; Kelly, P; Brown, R Journal: HemaSphere Issue: Volume 6(2022)Supplement 1 Page Start: 5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗